NO20030393L - Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler - Google Patents

Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler

Info

Publication number
NO20030393L
NO20030393L NO20030393A NO20030393A NO20030393L NO 20030393 L NO20030393 L NO 20030393L NO 20030393 A NO20030393 A NO 20030393A NO 20030393 A NO20030393 A NO 20030393A NO 20030393 L NO20030393 L NO 20030393L
Authority
NO
Norway
Prior art keywords
azoles
anilines
ullmann coupling
efficient ligand
mediated ullmann
Prior art date
Application number
NO20030393A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030393D0 (no
Inventor
Jia Cheng Zhou
Pasquale N Confalone
Hui-Yin Li
Lynette M Oh
Lucius T Rossano
Charles G Clark
Christopher A Teleha
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20030393D0 publication Critical patent/NO20030393D0/no
Publication of NO20030393L publication Critical patent/NO20030393L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/38One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Executing Machine-Instructions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20030393A 2000-07-26 2003-01-24 Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler NO20030393L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22093200P 2000-07-26 2000-07-26
PCT/US2001/023541 WO2002008199A2 (en) 2000-07-26 2001-07-26 Efficient ligand-mediated ullmann coupling of anilines and azoles

Publications (2)

Publication Number Publication Date
NO20030393D0 NO20030393D0 (no) 2003-01-24
NO20030393L true NO20030393L (no) 2003-03-24

Family

ID=22825611

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030393A NO20030393L (no) 2000-07-26 2003-01-24 Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler

Country Status (22)

Country Link
US (1) US6541639B2 (ru)
EP (1) EP1307431B1 (ru)
JP (1) JP2004504384A (ru)
KR (1) KR20030060872A (ru)
CN (1) CN1444565A (ru)
AT (1) ATE307804T1 (ru)
AU (1) AU2001280813A1 (ru)
BR (1) BR0112746A (ru)
CA (1) CA2417426A1 (ru)
DE (1) DE60114424T2 (ru)
EC (1) ECSP034453A (ru)
ES (1) ES2251501T3 (ru)
HU (1) HUP0301699A3 (ru)
IL (1) IL153547A0 (ru)
IS (1) IS6695A (ru)
MX (1) MXPA03000686A (ru)
NO (1) NO20030393L (ru)
NZ (1) NZ523271A (ru)
PL (1) PL361233A1 (ru)
RU (1) RU2003103706A (ru)
WO (1) WO2002008199A2 (ru)
ZA (1) ZA200300039B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2272813T3 (en) * 2001-04-24 2017-02-27 Massachusetts Inst Of Tech (Mit) COPPER CATALYST CREATION OF CARBON OXYGEN COMPOUNDS
CN101613321A (zh) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
EP1509502A1 (fr) * 2002-05-31 2005-03-02 Rhodia Chimie Procede de formation d une liaison carbone-carbone ou carbone-heteroatome
WO2004013094A2 (en) 2002-08-02 2004-02-12 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20090012300A1 (en) * 2004-07-16 2009-01-08 Mathilda Maria Henrica Lambers Process for the Preparation of an (Hetero) Arylamine
KR102372149B1 (ko) 2007-03-12 2022-03-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
KR102495941B1 (ko) 2013-12-03 2023-02-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
PT3125893T (pt) 2014-04-04 2023-11-21 Intra Cellular Therapies Inc Gama-carbolinas fusionadas com heterociclo deuterado como antagonistas de recetores 5-ht2a
MX2016013046A (es) 2014-04-04 2017-02-15 Intra Cellular Therapies Inc Compuestos organicos.
WO2015171951A1 (en) * 2014-05-07 2015-11-12 The Regents Of The University Of Colorado, A Body Corporate 2-(4-aryl-1h-imidazol-1-yl)aniline compounds
KR20180099905A (ko) 2016-01-26 2018-09-05 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
IL297676B2 (en) 2016-03-25 2023-12-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規共結晶
EP3525763A4 (en) 2016-10-12 2020-06-17 Intra-Cellular Therapies, Inc. AMORPHE FIXED DISPERSIONS
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018175969A1 (en) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
IL272249B2 (en) 2017-07-26 2023-11-01 Intra Cellular Therapies Inc organic compounds
WO2019023063A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
WO2019241278A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3843738A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3141223A1 (en) 2019-07-07 2021-01-14 Sharon Mates Novel methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372658A (ja) 1986-09-17 1988-04-02 Sumitomo Chem Co Ltd ニトロジフエニルアミン類の製造方法
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
CN1444565A (zh) 2003-09-24
ZA200300039B (en) 2004-04-02
BR0112746A (pt) 2003-09-09
PL361233A1 (en) 2004-10-04
ES2251501T3 (es) 2006-05-01
US20020099225A1 (en) 2002-07-25
WO2002008199A2 (en) 2002-01-31
IL153547A0 (en) 2003-07-06
ECSP034453A (es) 2003-03-31
EP1307431A2 (en) 2003-05-07
CA2417426A1 (en) 2002-01-31
DE60114424D1 (de) 2005-12-01
JP2004504384A (ja) 2004-02-12
ATE307804T1 (de) 2005-11-15
NO20030393D0 (no) 2003-01-24
KR20030060872A (ko) 2003-07-16
RU2003103706A (ru) 2004-08-10
MXPA03000686A (es) 2003-06-06
NZ523271A (en) 2005-01-28
EP1307431B1 (en) 2005-10-26
IS6695A (is) 2003-01-22
HUP0301699A3 (en) 2004-03-29
HUP0301699A2 (hu) 2003-12-29
WO2002008199A3 (en) 2002-06-13
US6541639B2 (en) 2003-04-01
AU2001280813A1 (en) 2002-02-05
DE60114424T2 (de) 2006-07-27

Similar Documents

Publication Publication Date Title
NO20030393L (no) Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler
PT1131318E (pt) Processo para a producao de pirazoles 5-substituidos utilizando ditietanos
GB0130341D0 (en) Compounds
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
CY1112442T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
IS7258A (is) Arýloxýfenýl og arýlsúlfanýlfenýl afleiður
EA200001129A2 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
ATE318189T1 (de) Reinigungsverfahren welches ultraschallwellen verwendet
MY137541A (en) Polymerization catalyst activators, method of preparing, and their use in polymerization processes
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
AU2003290592A1 (en) Antitumor benzoylsulfonamides
NO20000475D0 (no) Fremgangsmåte for bruk av korrosjonsinhibitorsammensetninger og prosess for fremstilling av disse
IT1311813B1 (it) Procedimento ed apparecchiatura per la fabbricazione di lastre inmateriale lapideo.
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
DK1200408T3 (da) Vedhæftningsmiddel
NO20033921L (no) Inhibitor av monoaminopptak
EP1476149A4 (en) SUBSTITUTED HYDRAZONES AS INHIBITORS OF CYCLOOXYGENASE-2
AU2002258437A1 (en) Peptide deformylase inhibitors
NO20006205D0 (no) Morfin-6-glukuronidsyntese
AU2003304490A1 (en) Peptide deformylase inhibitors
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
AU2002322035A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application